BR0316948A - Composto, formulação farmacêutica, e, uso de um composto - Google Patents
Composto, formulação farmacêutica, e, uso de um compostoInfo
- Publication number
- BR0316948A BR0316948A BR0316948-0A BR0316948A BR0316948A BR 0316948 A BR0316948 A BR 0316948A BR 0316948 A BR0316948 A BR 0316948A BR 0316948 A BR0316948 A BR 0316948A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical formulation
- amelioration
- diastereomers
- enantiomer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003667 hormone antagonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43270102P | 2002-12-11 | 2002-12-11 | |
| PCT/US2003/037071 WO2004052848A1 (en) | 2002-12-11 | 2003-12-03 | Novel mch receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316948A true BR0316948A (pt) | 2005-10-18 |
Family
ID=32507985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316948-0A BR0316948A (pt) | 2002-12-11 | 2003-12-03 | Composto, formulação farmacêutica, e, uso de um composto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7132456B2 (enExample) |
| EP (1) | EP1572637A1 (enExample) |
| JP (1) | JP2006509801A (enExample) |
| CN (1) | CN1726189A (enExample) |
| AU (1) | AU2003302925A1 (enExample) |
| BR (1) | BR0316948A (enExample) |
| CA (1) | CA2509042A1 (enExample) |
| MX (1) | MXPA05006272A (enExample) |
| WO (1) | WO2004052848A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7446204B2 (en) | 2004-10-08 | 2008-11-04 | H. Lundbeck A/S | Amino substituted aryloxybenzylpiperidine derivatives |
| US7329656B2 (en) | 2004-10-08 | 2008-02-12 | H. Lundbeck A/S | Arylthiobenzylpiperidine derivatives |
| JP5072602B2 (ja) * | 2004-12-17 | 2012-11-14 | イーライ リリー アンド カンパニー | Ｍｃｈ受容体アンタゴニストとしてのチアゾロピリジノン誘導体 |
| CN101184732B (zh) | 2005-03-28 | 2012-05-16 | 株式会社半导体能源研究所 | 蒽衍生物、发光元件用材料、发光元件、发光装置和电子器件 |
| US7731377B2 (en) * | 2006-03-21 | 2010-06-08 | Semiconductor Energy Laboratory Co., Ltd. | Backlight device and display device |
| US20070225176A1 (en) * | 2006-03-27 | 2007-09-27 | Pope Gary A | Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells |
| US7772162B2 (en) | 2006-03-27 | 2010-08-10 | Board Of Regents, The University Of Texas System | Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells |
| EP2301923B1 (en) | 2006-03-31 | 2016-06-08 | Novartis AG | Pyridine derivatives as dgat inhibitors |
| CN102516115B (zh) | 2006-08-09 | 2016-05-11 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
| WO2008026614A1 (en) | 2006-08-30 | 2008-03-06 | Semiconductor Energy Laboratory Co., Ltd. | Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device |
| CN101821305A (zh) * | 2007-03-23 | 2010-09-01 | 德克萨斯州立大学董事会 | 用溶剂处理地层的方法 |
| US7723722B2 (en) | 2007-03-23 | 2010-05-25 | Semiconductor Energy Laboratory Co., Ltd. | Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative |
| CN101835872B (zh) * | 2007-03-23 | 2014-06-18 | 德克萨斯州立大学董事会 | 处理含烃地层的方法 |
| US20080286445A1 (en) * | 2007-05-17 | 2008-11-20 | Semiconductor Energy Laboratory Co., Ltd. | Composition, and method of fabricating light-emitting element |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| US8261825B2 (en) * | 2007-11-30 | 2012-09-11 | Board Of Regents, The University Of Texas System | Methods for improving the productivity of oil producing wells |
| CN102089282A (zh) * | 2008-07-08 | 2011-06-08 | 株式会社半导体能源研究所 | 咔唑衍生物、发光元件用材料、发光元件以及发光装置 |
| EP2330097B1 (en) * | 2008-09-19 | 2013-01-23 | Semiconductor Energy Laboratory Co, Ltd. | Carbazole derivative and method for producing the same |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| MY159058A (en) | 2011-02-25 | 2016-12-15 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent |
| EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| KR102844041B1 (ko) | 2016-02-26 | 2025-08-11 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2025101724A1 (en) | 2023-11-09 | 2025-05-15 | Chevron Phillips Chemical Company Lp | Systems and methods for chromium catalyst activation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3535330A (en) * | 1968-04-29 | 1970-10-20 | Sandoz Ag | 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof |
| US3928449A (en) * | 1969-04-03 | 1975-12-23 | Sandoz Ag | Aminoalkoxy-terphenyls and the salts thereof |
| LU78484A1 (de) * | 1977-11-10 | 1979-06-13 | Ciba Geigy Ag | Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen |
| DE2752361A1 (de) * | 1977-11-24 | 1979-06-07 | Troponwerke Gmbh & Co Kg | Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
-
2003
- 2003-12-03 AU AU2003302925A patent/AU2003302925A1/en not_active Abandoned
- 2003-12-03 CA CA002509042A patent/CA2509042A1/en not_active Abandoned
- 2003-12-03 JP JP2004559142A patent/JP2006509801A/ja not_active Withdrawn
- 2003-12-03 MX MXPA05006272A patent/MXPA05006272A/es unknown
- 2003-12-03 CN CNA2003801059746A patent/CN1726189A/zh active Pending
- 2003-12-03 EP EP03812783A patent/EP1572637A1/en not_active Withdrawn
- 2003-12-03 BR BR0316948-0A patent/BR0316948A/pt not_active Application Discontinuation
- 2003-12-03 US US10/536,053 patent/US7132456B2/en not_active Expired - Fee Related
- 2003-12-03 WO PCT/US2003/037071 patent/WO2004052848A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1726189A (zh) | 2006-01-25 |
| US20060052449A1 (en) | 2006-03-09 |
| US7132456B2 (en) | 2006-11-07 |
| AU2003302925A1 (en) | 2004-06-30 |
| MXPA05006272A (es) | 2005-08-19 |
| CA2509042A1 (en) | 2004-06-24 |
| EP1572637A1 (en) | 2005-09-14 |
| JP2006509801A (ja) | 2006-03-23 |
| WO2004052848A1 (en) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0316948A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| BRPI0417771A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóides | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| BRPI0408990A (pt) | derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase | |
| BRPI0410563A (pt) | derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| SE0001899D0 (sv) | New compounds | |
| BR0308429A (pt) | Aroilpiridinonas monocìclicas como agentes antiinflamatórios | |
| BRPI0416628A (pt) | uso de compostos orgánicos | |
| MY148108A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| BRPI0409211A (pt) | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| BRPI0407097A (pt) | Antagonista do casr | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| BRPI0415713A (pt) | mio-inositol hexafosfato para uso tópico | |
| BRPI0517425A (pt) | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| BRPI0408295A (pt) | uso de um composto | |
| SE0102440D0 (sv) | New compound | |
| TW200606164A (en) | New compounds | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| BR0011880A (pt) | Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |